Statin Therapy for Patients With Cardiovascular Disease (SPC)

SUMMARY OF CHANGES TO HEDIS 2018

- Clarified that the pregnancy required exclusion should be applied to only female members.
- Replaced medication table references with references to medication lists.

Description

The percentage of males 21–75 years of age and females 40–75 years of age during the measurement year, who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. The following rates are reported:

1. *Received Statin Therapy.* Members who were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year.

2. *Statin Adherence 80%.* Members who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period.

Definitions

IPSD	Index prescription start date. The earliest prescription dispensing date for any statin medication of at least moderate intensity during the measurement year.
Treatment period	The period of time beginning on the IPSD through the last day of the measurement year.
PDC	Proportion of days covered. The number of days the member is covered by at least one statin medication prescription of appropriate intensity, divided by the number of days in the treatment period.
Calculating number of days covered for multiple prescriptions	If multiple prescriptions for different medications are dispensed on the same day, calculate the number of days covered by a statin medication (for the numerator) using the prescriptions with the longest days supply. For multiple different prescriptions dispensed on different days with overlapping days supply, count each day in the treatment period only once toward the numerator.
	If multiple prescriptions for the same medication are dispensed on the same day or on different days, sum the days supply and use the total to calculate the number of days covered by a statin medication (for the numerator). For example, three prescriptions for the same medication are dispensed on the same day, each with a 30-day supply. Sum the days supply for a total of 90 days covered by a statin. Subtract any days supply that extends beyond December 31 of the measurement year.
	Use the Drug ID field in the Medication List Directory of NDC codes to determine if the prescriptions are the same or different.

Eligible Population: Rate 1—Received Statin Therapy

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 20: Members in Hospice.

Product line	Commercial, Medicaid, Medicare (report each product line separately).
Age	Report two age/gender stratifications and a total rate.

> - Males 21–75 years as of December 31 of the measurement year.
> - Females 40–75 years as of December 31 of the measurement year.
> - Total.

Continuous enrollment	The measurement year and the year prior to the measurement year.
Allowable gap	No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
Anchor date	December 31 of the measurement year.
Benefit	Medical. Pharmacy during the measurement year.
Event/Diagnosis	Follow the steps below to identify the eligible population.
Step 1	Members are identified for the eligible population in two ways: by event or by diagnosis. The organization must use *both* methods to identify the eligible population, but a member only needs to be identified by one method to be included in the measure.

Event. Any of the following during the year prior to the measurement year meet criteria:

- *MI.* Discharged from an inpatient setting with an MI (MI Value Set). To identify discharges:
    1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
    2. Identify the discharge date for the stay.
- *CABG.* Members who had CABG (CABG Value Set) in any setting.
- *PCI.* Members who had PCI (PCI Value Set) in any setting.
- *Other revascularization.* Members who had any other revascularization procedures (Other Revascularization Value Set) in any setting.

Diagnosis. Identify members as having ischemic vascular disease (IVD) who met at least one of the following criteria during both the measurement year and the year prior to the measurement year. Criteria need not be the same across both years.

- At least one outpatient visit (Outpatient Value Set) with an IVD diagnosis (IVD Value Set), *or*
- At least one acute inpatient encounter (Acute Inpatient Value Set) with an IVD diagnosis (IVD Value Set).

Step 2:
Required
exclusions

Exclude members who meet any of the following criteria:

- Female members with a diagnosis of pregnancy (Pregnancy Value Set) during the measurement year or the year prior to the measurement year.
- In vitro fertilization (IVF Value Set) in the measurement year or year prior to the measurement year.
- Dispensed at least one prescription for clomiphene (Estrogen Agonist Medications List) during the measurement year or the year prior to the measurement year.
- ESRD (ESRD Value Set) during the measurement year or the year prior to the measurement year.
- Cirrhosis (Cirrhosis Value Set) during the measurement year or the year prior to the measurement year.
- Myalgia, myositis, myopathy or rhabdomyolysis (Muscular Pain and Disease Value Set) during the measurement year.

Estrogen Agonist Medications

Description	Prescription
Estrogen agonists	• Clomiphene

Administrative Specification: Rate 1—Received Statin Therapy

Denominator   The Rate 1 eligible population.

Numerator   The number of members who had at least one dispensing event for a high-intensity or moderate-intensity statin medication (High and Moderate-Intensity Statin Medications List) during the measurement year.

High- and Moderate-Intensity Statin Medications

Description	Prescription	
High-intensity statin therapy	• Atorvastatin 40-80 mg • Amlodipine-atorvastatin 40-80 mg • Ezetimibe-atorvastatin 40-80 mg	• Rosuvastatin 20-40 mg • Simvastatin 80 mg • Ezetimibe-simvastatin 80 mg
Moderate-intensity statin therapy	• Atorvastatin 10-20 mg • Amlodipine-atorvastatin 10-20 mg • Ezetimibe-atorvastatin 10-20 mg • Rosuvastatin 5-10 mg • Simvastatin 20-40 mg • Ezetimibe-simvastatin 20-40 mg • Niacin-simvastatin 20-40 mg	• Sitagliptin-simvastatin 20-40 mg • Pravastatin 40-80 mg • Lovastatin 40 mg • Niacin-lovastatin 40 mg • Fluvastatin XL 80 mg • Fluvastatin 40 mg bid • Pitavastatin 2–4 mg

Eligible Population: Rate 2—Statin Adherence 80%

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 20: Members in Hospice.

Product line	Commercial, Medicaid, Medicare (report each product line separately).
Age	Report two age/gender stratifications and a total rate. • Males 21–75 years as of December 31 of the measurement year. • Females 40–75 years as of December 31 of the measurement year. • Total.
Continuous enrollment	The measurement year and the year prior to the measurement year.
Allowable gap	No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
Anchor date	December 31 of the measurement year.
Benefit	Medical. Pharmacy during the measurement year.
Event/ diagnosis	All members who meet the numerator criteria for Rate 1.

Administrative Specification: Rate 2—Statin Adherence 80%

Denominator	The Rate 2 eligible population.
Numerator	The number of members who achieved a PDC of at least 80% during the treatment period. Follow the steps below to identify numerator compliance.

Step 1   Identify the IPSD. The IPSD is the earliest dispensing event for any high-intensity or moderate-intensity statin medication (High and Moderate-Intensity Statin Medications List) during the measurement year.

Step 2   To determine the treatment period, calculate the number of days beginning on the IPSD through the end of the measurement year.

Step 3   Count the days covered by at least one prescription for any high-intensity or moderate-intensity statin medication (High and Moderate-Intensity Statin Medications List) during the treatment period. To ensure that days supply that extends beyond the measurement year is not counted, subtract any days supply that extends beyond December 31 of the measurement year.

Step 4   Calculate the member's PDC using the following equation. Round (using the .5 rule) to two decimal places.

$$\frac{\text{Total Days Covered by a Statin Medication in the Treatment Period (step 3)}}{\text{Total Days in Treatment Period (step 2)}}$$

Step 5   Sum the number of members whose PDC is ≥80% for the treatment period.

Note

- *All members who are numerator compliant for Rate 1 must be used as the eligible population for Rate 2 (regardless of the data source used to capture the Rate 1 numerator). For example, if supplemental data were used to identify compliance for the Rate 1 numerator, then supplemental data will be included in identifying the Rate 2 eligible population.*

Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

Table SPC-1/2/3: Data Elements for Statin Therapy for Patients With Cardiovascular Disease

Data Elements	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	Each rate, for each age/gender stratification and total
Number of required exclusions	Rate 1, for each age/gender stratification and total
Numerator events by administrative data	Each rate, for each age/gender stratification and total
Numerator events by supplemental data	Each rate, for each age/gender stratification and total
Reported rate	Each rate, for each age/gender stratification and total
Lower 95% confidence interval	Each rate, for each age/gender stratification and total
Upper 95% confidence interval	Each rate, for each age/gender stratification and total